Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

odanacatib

Known as: (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)pentanamide 
An inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Osteoporosis is an enormous and growing public health problem. Once considered an inevitable consequence of ageing, it is now… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2016
Highly Cited
2016
  • Asher Mullard
  • Nature Reviews Drug Discovery
  • 2016
  • Corpus ID: 10186583
drugs with new mechanisms of action. Novel drugs accounted for 27% of the phase III cardiovascular candidates in 1990, and 57% of… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
SummaryOdanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal osteoporosis. Phase 2 data indicate… Expand
  • table 1
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Odanacatib (ODN) is a selective inhibitor of the collagenase cathepsin K that is highly expressed by osteoclasts. In this 2-year… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Odanacatib (ODN) is a selective and reversible inhibitor of cathepsin K (CatK) currently being developed as a once-weekly… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
The selective cathepsin K inhibitor odanacatib (ODN) progressively increased bone mineral density (BMD) and decreased bone… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Odanacatib (ODN) is a selective, potent and reversible inhibitor of cathepsin K (CatK) that inhibits bone loss in postmenopausal… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Metastatic bone disease (MBD) is a frequent complication in patients with breast cancer and is associated with… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Cathepsin K, a cysteine protease expressed in osteoclasts, degrades type 1 collagen. Odanacatib selectively and reversibly… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of… Expand
Is this relevant?